Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

orted more commonly in the placebo arm. During the study, one death in the everolimus arm occurred due to convulsion, though it was not considered related to the study drug by the investigator(1).

EXIST-2 enrolled 118 patients in the US, Germany, the Netherlands, Japan, the UK, Russia, Italy, Canada, Poland, Spain and France. This study is part of a Phase III trial program investigating everolimus in the various manifestations of TSC(1,10).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown.

Afinitor is also approved in the US for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and for the treatment of progressive neuroendocrine tumors of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease. The US Food and Drug Administration (FDA) determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established.

In the US, everolimus is available from Novartis in different dosage strengths and for different uses in non-oncology patient populations under the trade name Zortress®. Everolimus is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents.

Not all indications are available in every country. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. As an investigational compound, the safety and efficacy profile o
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... the second half of this yearBERLIN and TARRYTOWN, N.Y., ... Inc. (Nasdaq: REGN ) today announced that ... VEGF Trap-Eye, an investigational agent for the treatment of ... (CRVO). The companies plan to initiate a Phase 3 ...
... Investing in New Product Presentations for PatientsSAN DIEGO and ... AMLN ) and Eli Lilly and Company (NYSE: ... have agreed in principle to the terms of a ... device. Separately, the companies announced that they have initiated ...
Cached Medicine Technology:Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 2Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 3Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 4Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 6Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 7
(Date:7/12/2014)... Praeclarus Press is excited to ... new resource for women in need of lactation support. ... away from their children. Today’s mothers receive very clear ... but often feel unsupported when it comes to balancing ... evidence-based insights, and written by Nancy Mohrbacher, an international ...
(Date:7/12/2014)... Angeles, CA (PRWEB) July 12, 2014 ... buyer power score of 4.1 out of 5. ... market that have been underpinning buyer negotiation power ... IBISWorld procurement analyst Anna Son, “during the period, ... with rising costs associated with new product development, ...
(Date:7/12/2014)... July 12, 2014 Ladies, it doesn't matter ... there. Those who are looking for an affordable gown can ... special occasion dresses) to get their dream items. Recently, the ... tea length gowns . Along with that, it is also ... enjoy the special offer; the deadline of this promotion is ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
(Date:7/11/2014)... 11, 2014 As transvaginal mesh ... Johnson & Johnson’s Ethicon Inc. unit continue to ... that the Texas Attorney General’s Office has acknowledged ... surgical mesh products used to treat pelvic organ ... report from kens5.com, the probe began nearly two ...
Breaking Medicine News(10 mins):Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... with chronic obstructive pulmonary disease (COPD) who are hospitalized ... decreased mortality when compared to those who are not ... almost 16,000 COPD patients admitted to VA hospitals. ... edition of the American Thoracic Society,s American Journal ...
... FRIDAY, April 15 (HealthDay News) -- Is estrogen breast cancer,s ... Journal of the American Medical Association , which analyzed data ... when it found a reduced risk of breast cancer in ... This seemed to contradict years of cautions that estrogen therapy ...
... , FRIDAY, April 15 (HealthDay News) -- Losing weight can ... obese, but not all diet plans are effective in lowering ... against cancer are those that encourage long-term changes in eating ... food groups, explained Daxaben Amin, a senior clinical dietitian in ...
... New York, N.Y. (April 15, 2011) A comprehensive ... Autism Tissue Program (ATP), a postmortem brain tissue donation ... autism also had epilepsy, and co-morbidity data from the ... than expected rate of mortality in individuals with both ...
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) -- Seniors ... with their neighbors stand a much better chance of surviving ... each increase in what researchers call neighborhood "cohesion," such as ... on a neighbor for help, the odds of survival after ...
... elective surgery reduces potentially serious kidney complications, according to ... Journal of the American Society Nephrology (JASN). ... surgeries are performed around the world. Unfortunately, many patients ... surgery, often due to decreased blood flow to the ...
Cached Medicine News:Health News:Large study finds ICS therapy reduces pneumonia mortality 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 2Health News:Estrogen's Role in Breast Cancer Can Fluctuate 3Health News:A Good Diet Includes Many Cancer-Fighting Foods: Expert 2Health News:Mortality rate is increased in persons with autism who also have epilepsy 2Health News:Close-Knit Neighborhoods Raise Chances of Stroke Survival 2Health News:Statins may protect against kidney complications following elective surgery 2
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Straight double action bone cutting rongeur....
Beuse Zygomatic Arch Awl with slightly curved tip....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: